Microphysiological system to advance adoptive cell therapy
Novel BEL microphysiological system helps to improve process of identifying potent anti-tumor immune cells and corresponding targets and bridges gap between in-vitro and in-vivo studies.
Adoptive cell therapy has emerged as promising cancer treatment in recent years. Despite its advantages, clinical applications of this patient-specific therapy face, however, many challenges. A novel microfluidic platform, developed in our group in collaboration with members from Timm Schroeder’s group (O. Nguyen, P. Misun, C. Lohasz, J. Lee, W. Wang, T. Schroeder, and A. Hierlemann, "An immunocompetent microphysiological system to simultaneously investigate effects of anti-tumor natural killer cells on tumor and cardiac microtissues", Frontiers in Immunology 2021, Vol. 12, p. 5171) will help to improve the process of identifying potent anti-tumor immune cells and their corresponding targets. It is aimed at bridging the gap between in-vitro and in-vivo studies.
external page Frontiers Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
external page Link to scientific paper in Frontiers Immunology